18
Maximizing Protein Production Efficiency in Cancer Therapeutics Katherine Thomas

Summer Research Presentation 2013 Final

Embed Size (px)

Citation preview

Maximizing Protein Production Efficiency in Cancer Therapeutics Katherine Thomas

Pancreatic Cancer

445,220

PANCAN Pancreatic Cancer Fact Sheet 2013

TRAIL •  TNF-related apoptosis-inducing ligand •  Induces apoptosis by binding to an

extrinsic death receptor •  In order to be active, TRAIL must form a

homotrimer •  TRAIL therapies are more effective in

cancer cells than human cells A Genetically Encoded Multifunctional TRAIL Trimer Facilitates Cell-Specific Targeting and Tumor Cell Killing;

2010

Shepard B et al. Anti-Infective Agents in Medicinal Chemistry 2010;8:87-101

TRAIL •  Non-covalently bonded

TRAIL is sensitive to degredation

•  Must form a homotrimer in order to become active

TR3 •  Covalently-linked trimer

developed through genetic fusion

•  Can be further genetically modified

TR3 is a powerful inducer of apoptosis.

Spitzer D et al. Mol Cancer Ther 2010;9:2142-2151

Target Proteins

•  Surface proteins •  Over-expressed in pancreatic and ovarian

cancer cells

Mesothelin MUC16

http://www.epitomics.com/images/IVD/AC-0130_ihc_17343_large.jpg http://www.mybiosource.com/images/tds/protocol_images/MBS245325_IH.jpg

FhMeso1-TR3

Targeting

Targeting

Meso-TR3 TR3

Garg et al

Need for Mass Production

Signal Peptides

•  Leader sequences •  Direct protein to

secretory pathway •  Destination: Golgi

http://www.nobelprize.org/nobel_prizes/medicine/laureates/1999/illpres/protein.html

Kozak Sequence •  Initiation of translation •  Contains start codon

http://www.biomedcentral.com/content/supplementary/1471-2164-13-21-s9.png

Results

pTR3

cd59 signal peptide cd59 signal peptide

Kozak sequence

pTR3-mod59

cd59 signal peptide Kozak sequence

pTR3-mod59

Honeybee melittin signal peptide

Kozak sequence

pTR3-Mel

LEX signal peptide Kozak sequence

pTR3-LEX

Future Research •  Mass Drug Production

–  In-vivo – Clinical Trials

•  Genetic Modification – Target Proteins – Cancer Stem Cells – Additional Drugs

Acknowledgements

•  Dr. Hawkins •  Dr. Spitzer •  Jesse Gibbs •  Christy Hornick

Thank You